Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ëàáîðàòîðíàÿ äèàãíîñòèêà

Ëàáîðàòîðíàÿ äèàãíîñòèêà Ôîðóìû: Ôîðóì äëÿ îáùåíèÿ âðà÷åé è ñïåöèàëèñòîâ, Ìèêðîáèîëîãèÿ äëÿ êëèíèöèñòîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 26.05.2003, 20:06
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
ÏÖÐ,ÈÔÀ äèàãíîñòèêà ïîëîâûõ èíôåêöèé

Ïåðåä ïîäãîòîâêîé ê áåðåìåííîñòè âðà÷è ãèíåêîëîãè îáû÷íî ðåêîìåíäóþò ñäàòü àíàëèçû íà èíôåêöèè - õëàìèäèþ,ìèêîïëàçìó,óðåîïëàçìó,ãàðäíåðåëëó,òîêñîïë àçìó,öèòîìåãàëîâèðóñ,âèðóñ ïðñòîãî ãåðïåñà - ìåòîäîì ÏÖÐ (àíòèãåíû) è ÈÔÀ(àíòèòåëà Ig G, Ig M).
 ïðàéñ ëèñòå îäíîãî èç ãîëîâíûõ èíñòèòóòîâ, ìåòîäîì ÏÖÐ áåðóò ñîñêîá,ìàçîê,ìî÷ó,áèîïòàò,ñèíîâèàëüíóþ æèäêîñòü,êðîâü.
Âîïðîñ.
Êàêèå ìåòîäû çàáîðà èñïîëüçóþòñÿ - ñîñêîá,ìàçîê,ìî÷à,êðîâü - âñå èç ïåðå÷èñëåííûõ,èëè êàêèå âîçìîæíû ñî÷åòàíèÿ èõ ?
( àíàìíåçå 2 íåðàçâèâàþùèå áåðåìåííîñòè,õðîíè÷åñêèé öèñòèò).
Îòâåòèòü ìîæíî ïî ìåäèöèíñêè (ñàìà ìåäèê).
Çàðàíåå ñïàñèáî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 27.05.2003, 10:51
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Èðèíà!
Âçãëÿíèòå íà Âàøè ïðåäûäóùèå ïîñòèíãè, ðàçâåøåííûå â ðàçíîå âðåìÿ ïî ðàçíûì ðàçäåëàì. Ìîæåò âàøè ïðîáëåìû íå ñâÿçàíû ñ íàëè÷èåì ìèêðîîðãàíèçìîâ ëîêàëüíî èëè ïîâñåìåñòíî, à îáóñëîâëåíû íàïð. íàëè÷èåì àíòèôîñôîëèïèäíûõ/àíòèêàðäèîëèïèäíûõ àíòèòåë? Äàëåå, õð. öèñòèò è äð. èíôåêöèè ìî÷åâûäåëèòåëüíîé ñèñòåìû ìîãóò òàêæå áûòü îáóñëîâëåíû ëàòåíòíûì æåëåçîäåôèöèòîì:
East Mediterr Health J 1999 Mar;5(2):344-9
Iron status of Libyan infants with urinary tract infection.
el-Foghy Z, Sagher F, al-Agili S.
Serum iron, serum total iron binding capacity and tranferrin saturation levels were measured in 45 infants, of whom 19 had urinary tract infections confirmed by positive suprapubic aspiration. The control group comprised 26 healthy infants with negative results. Mean serum iron and transferrin saturation values were significantly lower in infants with urinary tract infection compared with the control group (P < 0.01 and P < 0.001 respectively), especially if the cultured organism was Escherichia coli (P < 0.01, P < 0.02). Total iron binding capacity was within the normal range.
Êðîìå òîãî, ñóùåòâóþò òàê íàçûâàåìûå àáàêòåðèàëüíûå è/èëè èíòåðñòèöèàëüíûå öèñòèòû:
Painful bladder diseases: interstitial or abacterial cystitis?
Lancet. 1988 Feb 13;1(8581):337-8. Review.

Theoharides TC, Sant GR.
New agents for the medical treatment of interstitial cystitis.
Expert Opin Investig Drugs. 2001 Mar;10(3):521-46. Review.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 27.05.2003, 14:03
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
Ñïàñèáî, ÷òî î÷åðåäíîé ðàç îáðàòèëè âíèìàíèå íà ìîå ñîîáùåíèå.Ê ñîæåëåíèþ,àíãëèéñêèì íå âëàäåþ,ïîýòîìó íå ñìîãëà ïðî÷åñòü Âàø òåêñò.
Åùå ðàç ñïàñèáî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 27.05.2003, 14:57
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Èðèíà!
Õîðîøî, äåëî íå â àíãëèéñêîì: íå ïîíèìàþ, ïî÷åìó Âàøè äîêòîðà ãèíåêîëîãè íå ðåêîìåíäóþò Âàì ïðîâåðèòüñÿ íà àíòèôîñôîëèïèäíûé ñèíäðîì èëè æå íà íàëè÷èå òðîìáîôèëèè, êîãäà ó Âàñ â àíàìíåçå 2 âûêèäûøà è/èëè âíóòðèóòðîáíûå îñòàíîâêè ðàçâèòèÿ/ñìåðòè ïëîäà? Åñëè îíè íå â ñîñòîÿíèè èëè îòñóòñòâóåò áàçà (â ò. ÷. è çíàíèé), òî ïî÷åìó áû Âàì ñàìîé êàê äîêòîðó íå ïîâåñòè ñåáÿ ñàìîé íà àñïèðèíå/ãåïàðèíå âî âðåìÿ áåðåìåííîñòè, äàáû åå äîíîñèòü? Âìåñòî òîãî, ÷òî áû òðàòèòü âðåìÿ/äåíüãè/íåðâû íà âñÿêèå èññëåäîâàíèÿ, êîòîðûå èìåþò âåñüìà ñîìíèòåëüíóþ öåííîñòü (íàñêîëüêî ïîíèìàþ ïîõîæèå àíàëèçû Âû óæå âûïîëíÿëè, êîãäà ïëàíèðîâàëè ïðåäûäóùóþ áåðåìåííîñòü?).
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 27.05.2003, 15:32
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êàê äàëåêî íå ñïåöèàëèñò, ïðîñòî âîçüìó íåñêîëüêî ïîñëåäíèõ ïóáëèêàöèé êîëëåã ãèíåêîëîãîâ èç-çà ðóáåæà è òàì ÿñíî íàïèñàíî, ÷òî ïî êðàéíåé ìåðå 50% ñïîíòàííûõ âûêèäûøåé (ïåðâûé òðèìåñòð) îáóñëîâëåí ãåíåòè÷åñêîé ïàòîëîãèåé, êðîìå òîãî, ïîâûøàþò ðèñê âûêèäûøåé ïðåêëîííûé âîçðàñò ìàòåðè, òî÷å÷í. ìóòàöèè âåäóùèå ê ôåíèëêåòîíóðèè èëè ãëþê6ôîñôàò-äåôèöèòó, ïàòîëîãèÿ ìàòêè, íåêîíòðîëèðóåìûé ÑÄ, ÀÔË ñèíäðîì è êóðåíèå.
Semin Reprod Med 2000;18(4):331-9
The epidemiology of recurrent pregnancy loss.
Cramer DW, Wise LA.
Íàèáîëåå ÷àñòûå ïðè÷èíû âûêèäûøåé âî 2 òðèìåñòðå: àíàòîì. äåôåêòû, öåðâèêàëüíàÿ íåäîñòàòî÷íîñòü, àóòîèììóííàÿ ïàòîëîãèÿ, âàãèíàëüíûå èíôåêöèè, óðîäñòâà ïëîäà.
Curr Opin Obstet Gynecol 1996 Dec;8(6):449-53
Recurrent second trimester miscarriage.
Flint S, Gibb DM.
Ëå÷åíèå ãåíèòàëüíûõ èíôåêöèé âî âðåìÿ áåðåìåííîñòè óìåíüøàåò ðèñê íåâûíàøèâàíèÿ/ïðåæäåâðåìåííûõ ðîäîâ.
Òê Âû íå óïîìèíàåòå î ñðîêàõ îñòàíîâîê Âàøèõ áåðåìåííîñòåé, âåñüìà òðóäíî ïðåäïîëàãàòü îá èõ âåðîÿòíûõ ïðè÷èíàõ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 27.05.2003, 18:31
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
È åùå îäíà íåäàâíÿÿ ïóáëèêàöèÿ ïî òåìå èç ßïîíèè: (ïî÷òè äîñëîâíûé ïåðåâîä)
Ñîîáùàåì î 2 ñëó÷àÿõ ëå÷åíèÿ ïîâòîðíûõ âûêèäûøåé íèçêîìîëåêóëÿðíûì ãåïàðèíîì: ó îäíîé ïàöèåíòêè áûëî 11 âûêèäûøåé, ó äðóãîé 8. Ïðåäûäóùåå ëå÷åíèå ïðåäíèçîëîíîì, àñïèðèíîì, èììóíèçàöèåé áûëî íåýôôåêòèâíûì. Òàêæå ó íèõ íå áûëî âûÿâëåíî íè àíòèôîñôîëèïèäíûõ àíòèòåë, íè âðîæäåííîé ñêëîííîñòè ê òðîìáîçàì. ÍÌà áûë íàçíà÷åí ñðàçó ïîñëå îïëîäîòâîðåíèÿ è ïðåêðàùåí â ñðîêå 34 íåäåëè: ó îáåèõ ðîäèëèñü çäîðîâûå äåòè.
Am J Reprod Immunol 2003 Feb;49(2):90-2
Successful pregnancy with low molecular weight heparin in two women with recurrent miscarriage of unknown etiology.
Miyashita Y, Waguri M, Nakanishi I, Suehara N, Fujita T.
Department of Maternal Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health, Murodo-cho, Izumi, Japan. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Íàäåþñü, Âàì íå ïðèäåòñÿ èäòè ïî ñòîïàì íåñ÷àñòíûõ, íî íàñòîé÷èâûõ ÿïîíîê, îñîáåííî â ñâåòå òîãî, ÷òî â ìèðîâîé ìåä ïðàêòèêå óæå îïðåäåëèëèñü ïî âåäåíèþ ïàöèåíòîê ñ ïðèâû÷íûì íåâûíàøèâàíèåì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 18.06.2003, 15:21
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
Ñïàñèáî çà äåòàëüíîå ðàññìîòðåíèå ïðîáëåìû. Ê ñîæåëåíèþ,îáñëåäîâàâøèñü ïî ïîëíîé ïðîãðàììå,âêëþ÷àþùåé - (Óçè ìàëîãî òàçà,íàäïî÷å÷íèêîâ,ùèòîâèäíîé æåëåçû,ãîðìîíû êðîâè (â òîì ÷èñëå íà ãèïåðàíäðîãåíåìèþ),ñïåðìîãðàììà ìóæà,àíàëèçû íà àíòèôîñôîëèïèäíûé ñèíäðîì è ÂÀ,ãåìîñòàçèîãðàììà,àíòèòåëà ê ÕÃ×,àíàëèç íà ãðóïïîâóþ ñîâìåñòèìîñòü,ÏÖÐ è ÈÔÀ äèàãíîñòèêà èíôåêöèé) ê ïðè÷èíå ïîâòîðíîé çàìåðøåé áåðåìåííîñòè ( ñðîê çàìåðàíèÿ 8 íåäåëü ïðè êàëåíäàðíîé áåðåìåííîñòè 13 íåäåëü) ïîêà íå ïðèøëè.
 áëèæàéøåå âðåìÿ ïëàíèðóåòñÿ äîáàâèòü ê ýòèì îáñëåäîâàíèÿì - êîíñóëüòàöèÿ ãåíåòèêà (êàðèîòèï+HLA òèïèðîâàíèå ìóæà è ìåíÿ),áåëêè ôåðòèëüíîñòè,áèîïñèÿ ýíäîìåòðèÿ,èññëåäîâàíèå ñìûâîâ ýíäîìåòðèÿ,Óçè ìàëîãî òàçà ñ îïðåäåëåíèåì (íå çíàþ êàê ãðàìîòíî ñêàçàòü) êðîâîòîêà â ìàòî÷íûõ ñîñóäàõ (íà ñêëîííîñòü ê ñïàñòè÷åñêèì ñîñòîÿíèÿì)-åñëè ÿ ïðàâèëüíî ïîíÿëà.Ìîæåòü áûòü çäåñü áóäåò êàêàÿ íèáóäü "çàöåïêà".
Åùå ðàç ñïàñèáî çà îòâåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 18.06.2003, 17:41
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ YBLOKO!
äëÿ äèàãíîñòèêè "âîë÷àíî÷íîãî" àíòèêîàãóëÿíòà èñïîëüçóåòñÿ À×Ò (ëó÷øå ñ íåáîëüøèì ñîäåðæàíèåì ôîñôîëèïèäîâ) èëè âðåìÿ ñâåðòûâàíèÿ, èíèöèèðîâàííîå ðàçâåäåííûì ÿäîì ãàäþêè Ðàññåëà. Ïîñëå ïîëó÷åíèÿ ðåçóëüòàòîâ ïðåâûøàþùèõ íîðìó, ïîâòîðÿþò èõ ñ äîáàâëåíèåì íîðì. ïóë-ïëàçìû - ðåçóëüòàòû òàêæå äîëæíû áûòü âûøå íîðìû è ëèø' ïðè äîáàâëåíèè ðàçìîðîæåííûõ òðîìáîöèòîâ èëè ñïåö. îêòîãîíàëüíûõ ôîñôîëèïèäîâ äîëæíû ðåçóëüòàòû íîðìàëèçîâàòüñÿ. Ýòî èññëåäîâàíèå äîëæíî áûòü ïîäòâåðæäåíî ÷åðåç 6-7 íåäåëü.
Òàêæå ìîãóò áûòü âûÿâëåíû àíòîêàðäèîëèïèíîâûå àíòèòåëà (àíòè-áåòà-2-ãëèêîïðîòåèí-1-îâûå àíòèòåëà) ëó÷øå IgG òèïà â óìåðåííîì èëè âûñîêîì òèòðå, òîæå ñ ïîâòîðåíèåì ÷åðåç 6-7 íåäåëü. Íå îáíàðóæåíèå îäíèõ íå ÿâëÿåòñÿ îñíîâàíèåì ê îòñóòñòâèþ ÀÔËÑ.
Ïîâîäîì äëÿ îáñëåäîâàíèÿ ÿâëÿåòñÿ íàëè÷èå òðîìáîçîâ â àíàìíåçå èëè 3 è áîëåå ñïîíòàííûõ âûêèäûøà íà ñðîêå ìåíåå 10 íåäåëü èëè áîëåå îäíîé âíóòðèóòðîáíîé îñòàíîâêè ðàçâèòèÿ íîðìàëüíîãî íà ÓÇÈ ïëîäà ñ äîêóìåíòèðîâàííûì ñåðäöåáèåíèåì íà ñðîêå áîëåå 10 íåäåëü (èçâèíèòå, íî ïî Âàøåìó ìåä. îïèñàíèþ "çàìåðàíèÿ" /÷òî çà òåðìèí-òî òàêîé!/ ýòî íå ñîâñåì ïîíÿòíî). Íàèáîëåå âûñîêèé ðèñê ïðåðûâàíèÿ áåðåìåííîñòè ïðè ÀÔËÑ - ýòî ôåòàëüíûé ïåðèîä (10 íåäåëü è áîëüøå), â òî âðåìÿ êàê ãåíåòè÷åñêè îáóñëîâëåííûå è ïðî÷èå îñòàíîâêè ïðîèñõîäÿò â ïðå- (ìåíåå 6 íåä.) è ýìáðèîííûé (ýìáðèîíè÷åñêèé?) (6-9 íåä.) ïåðèîäû.
Âàøèõ âíÿòíûõ àíàëèçîâ ïî ïîõîæåìó îáñëåäîâàíèþ (æåëàòåëüíî âûïîëíåííûõ äî áåðåìåííîñòè) íà àíòèôîñôîëèïèäíûé ñèíäðîì ÷òî-òî ïðèïîìíèòü íå ìîãó, äðóãèå ôèëüêèíû ãåìîñòàçèî/êîàãóëî-ãðàììû äëÿ ïîäòâåðæäåíèÿ/îïðîâåðæåíèÿ äèàãíîçà íå ãîäÿòñÿ.
Êðîìå òîãî, âðîæäåííûå òðîìáîôèëèè (äåôèöèò ïðîòåèíà S, óñòîé÷èâîñòü ê àêòèâèð. ïðîòåèíó Ñ [APCR]) ìîæåò áûòü ïðè÷èíîé âíóòðèóòðîáíîé îñòàíîâêè ðàçâèòèÿ ïëîäà â ïåðâîì òðèìåñòðå (ïîæàëóé òîæå íå â êàæäîé ëàáîðàòîðèè ñìîãóò îïðåäåëèòü óêàçàííûå ïàðàìåòðû).
Ëå÷åíèå â ïðèíöèïå îäíî: íèçêîìîëåêóëÿðíûé ãåïàðèí íà âåñü ïåðèîä áåðåìåííîñòè, àñïèðèí è ôîëèåâàÿ êèñëîòà (çàîäíî ïðîô-êà ïîðîêîâ ðàçâèòèÿ íåðâíîé òðóáêè). Ê òîìó æå êàê ìîæåì âèäåòü íà ïðèìåðå ìóæåñòâåííûõ ÿïîíîê íå âñåãäà óäàåòñÿ ðàñïîçíàòü ïî àíàëèçàì â ÷åì ïðè÷èíà-òî, à ÍÌà è çäåñü ïðèõîäèò íà ïîìîùü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 19.06.2003, 14:30
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
Âñå î÷åíü ñëîæíî, íî ïîñòîðàþñü ïîíÿòü.
Âîò ÍÅÊÎÒÎÐÛÅ ðåçóëüòàòû àíàëèçîâ,êîòîðûå ïîêà ÷òî ÿ ñäàëà ïîñëå 2-îé íåðàçâèâàþùåñÿ áåðåìåííîñòè (ÎÑÒÀËÜÍÛÅ Â ÐÀÁÎÒÅ).

1.
17-ÊÑ 13,0 (íîðìà 6,4-18,02) ìã/ñóò
òåñòîñòåðîí 0,48 (íîðìà 0,01-1,2) íã/ìë
ÄÃÝÀ-Ñ 1,8 (íîðìà 0,8-3,9) ìêã/ìë

2.Ãåìîñòàçèîãðàììà
êîë-âî òðîìáîöèòîâ 360 (íîðìà 180-420) òûñ./ìêë
àãðåãàöèÿ òðîìáîöèòîâ -
ÀÄÔ : ôóíêöèîíàëüíàÿ àêòèâíîñòü 31
(íîðìà 43-65) %
âðåìÿ 33
(íîðìà 35-60) ñåê
À×Ò 31,5 (íîðìà 20-40) ñåê
Ïðîòðîìáèí 100 (80-120) %
Ôèáðèíîãåí 3,5 (íîðìà2,0-4,0) ã/ë
ÐÊÌÔ 0,69 (íîðìà 0,28-0,46) åä. ýêñòèíêöèè
Òðîìáîýëàñòîãðàììà -
R+k 27(íîðìà 19-27) ìì
Ìà 55 (íîðìà 48-52) ìì
ÈÒÏ 21 (íîðìà20-40) ó.å.

3.Âîë÷àíî÷íûé àíòèêîàãóëÿíò
Òðîìáîïëàñòèíîâîå âðåìÿ 48,0
(íîðìà ìåíüøå èëè ðàâíî 45-55) ñåê
Êàîëèíîâîå âðåìÿ 51,5
(íîðìà ìåíüøå èëè ðàâíî 89) ñåê
Çìåèíûé ÿä 53,1
( íîðìà ìåíüøå èëè ðàâíî 45-55) ñåê

Çàêëþ÷åíèå:
Òðîìáîöèòàðíîå è ïëàçìåííîå çâåíüÿ ãåìîñòàçà áåç ïàòîëîãèè.Âîë÷àíî÷íûé àíòèêîàãóëÿíò íå îáíàðóæåí.

Åñëè Âàñ íå çàòðóäíèò ïðîêîììåíòèðóéòå ïîæàëóéñòà íà ìîåì ïðèìåðå,âñå ÷òî ñâÿçàííî ñ ïóíêòàìè 2,3 ýòîãî ñîîáùåíèÿ (âñå ëè çäåñü ñäàíî,ïðî àíòîêàðäèîëèïèíîâûå àíòèòåëà , ïðîòåèí S, óñòîé÷èâîñòü ê àêòèâèð. ïðîòåèíó Ñ ìíå âðà÷è íå÷åãî íå ñêàçàëè,îáÿçàòåëüíî ëè èõ ñäàâàòü.),÷òî òàêîå ÍÌÃ?
Åùå ðàç ñïàñèáî Dr. Vad.
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 19.06.2003, 17:03
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Èðèíà!
Ïî ïóíêòàì 2 è 3 ïðèäðàòüñÿ åñòü ê ÷åìó: îñíîâûâàÿñü, ÷òî àíàëèçû ýòè ïîëó÷åíû ÏÎÑËÅ (íå âî âðåìÿ) áåðåìåííîñòè íåñêîëüêî ìàëîâàòàÿ ÀÄÔ-èíä. àãðåãàöèÿ (õîòÿ ìû íå çíàåì íàñêîëüêî ñâåæèé è àêòèâíûé áûë ÀÄÔ), à òàêæå íå âèäèì áûëà ëè äåçàãðåãàöèÿ èëè íåò (ýôôåêòèâíîñòü àãðåãàöèè) ÷òî òàêîå "âðåìÿ 33" ??? äî íà÷àëà àãðåãàöèè ìíîãî, äî ìàêñèìàëüíîé - ìàëî, âðåìÿ ìàêñ. ñêîðîñòè - ìîæåò áûòü, íî äèàãíîñòè÷åñêè çà÷åì?; À×Ò - ñëèøêîì áîëüøîé ðàçáðîñ íîðì. ãðàíèö, áîëåå ïðèåìëåìûå 27-35 èëè 32-45; ïðîòðîìáèíîâûé èíäåêñ, ôèáðèíîãåí è ÐÊÌÔ õîòåëîñü áû ÷òî áû ó Bàñ áûëè ïîíèæå. Îïèðàÿñü íà äàííûå ÒÝà (ÌÀ âûøå íîðìû), ìîæíî çàïîäîçðèòü ó Âàñ ñêëîííîñòü ê ãèïåðêîàãóëàöèè èëè æå íåçíà÷èòåëüíóþ àêòèâàöèþ ñèñòåìû ñâåðòûâàíèÿ, äëÿ ïîäòâåðæäåíèÿ ýòîãî íåïëîõî áûëî áû îïðåäåëèòü Ä-äèìåðû.
Ïî ÂÀ (ï.3) êàê áû âñå ñïîêîéíî, íî âñå æå êàêîé çìåèíûé ÿä èñïîëüçîâàëñÿ, ïî÷åìó òàêàÿ ñòðàííàÿ íîðìà "ìåíüøå èëè ðàâíî 45-55", áîëåå åñòåñòâåííûå çíà÷åíèÿ ìåíåå 45, ìåíåå 55 èëè æå 45-55, ââèäó îòêëîíåíèé êîíå÷íî æå ôîñôîëèïèä-êîððèãèðèþùèõ ìåðîïðèÿòèé íå ïðîâîäèëè.
Èòàê ïîäâåäåì èòîãè. åñòü êîñâåííûå ïðèçíàêè (åñëè âåðèòü àíàëèçàì) àêòèâàöèè ñâåðòûâàíèÿ äàæå âíå áåðåìåííîñòè, íî ÂÀ íå âûÿâëåíû.
Ó÷èòûâàÿ àíàìíåç (à êñòàòè áûëè ëè òðîìáîçû â àíàìíåçå, ó ðîäèòåëåé, ïîñëå îïåðàöèé, òðàâì?), ìîæíî ïîäóìàòü èëè æå î íàëè÷èè àíòèêàðäèîëèïèíîâûõ àíòèòåë èëè æå î âðîæäåííîé òðîìáîôèëèè, åñëè âñå æå ñâÿçûâàòü ïðè÷èíó íåðàçâèâàþùèõñÿ áåðåìåííîñòåé ñ ãåìîñòàçîì.
ÒÝà è íåâûíàøèâàåìîñòüþ çàíèìàþòñÿ îäíè ñïåöû èç Àíãëèè (Lesley Regan and Raj Rai Department of Reproductive Science and Medicine, Imperial College School of Medicine at St. Mary's, Mint Wing, South Wharf Road, London W2 1NY, UK. / Thrombophilia and pregnancy loss / Journal of Reproductive Immunology Volume 55, Issues 1-2, May-June 2002, Pages 163-180), îíè ïèøóò ÷òî óâåëè÷åíèå ÌÀ ñâûøå 2 ñèãì îò ñðåäíèõ âåëè÷èí áûëî îáíàðóæåíî ó æåíùèõ ñ ïîâòîðíûìè âûêèäûøàìè. Åñëè âçÿòü Âàøè íîðìû ÒÝà (48-52) è âûðàçèòü êàê ìåäèàíà+/-ñèãìà òî ïîëó÷èòñÿ 50+/-2 è Âàøå çíà÷åíèå 55 êàê ðàç â 2,5 ðàçà âûøå ñèãìû. Íî ýòî òîëüêî ïðåäïîëîæåíèå, òê íå çíàþ íà êàêèõ ëþäÿõ ñîçäàâàëèñü íîðìû â ëàáîðàòîðèè, ãäå Âû îáñëåäîâàëèñü.
Ïîõîæå, ÷òî âñå æå çàêëþ÷åíèå ïî ïóíêòó 2 Âàì âûíåñëè íå ñîâñåì âåðíîå.
Òåïåðü î ÍÌÃ: íèçêîìîëåêóëÿðíûå ãåïàðèíû (ôðàêñèïàðèí, êëåêñàí, ôðàãìèí) ÿâëÿþòñÿ áîëåå óäîáíîé ôîðìîé ãåïàðèíà, òê ïðè íàçíà÷åíèè âî âðåìÿ áåðåìåííîñòè äîñòàòî÷íî îäíîé èíüåêöèè â äåíü (âìåñòî 3-4 îáû÷íîãî), ðåæå âûçûâàþò îñòåîïîðîç, òðîìáîöèòîïåíèþ.
Î ÀÊÀ è äð. àíòèôîñôîëèïèäíûõ ÀÒ, à òàêæå ÀÏÖ-Ð, ïðîòåèíàõ S, C èëè óðîâíå àíòèòðîìáèíà íåìíîãèå ñïåöèàëèñòû çíàþò, òåì áîëåå íå âñå ïðèçíàþò, è òåì áîëåå íå âåçäå ìîãóò èõ îïðåäåëèòü. Ïðè èõ îáíàðóæåíèè (à ïðè èõ îòñóòñòâèè ýòî íå èñêëþ÷èò ãåìîñòàç-çàâèñèìóþ ïðè÷èíó âûêèäûøåé, òê äàëåêî íå âñå òðîìáîôèëèè îáíàðóæåíû) âñå ðàâíî îäíà èç íåìíîãèõ âîçìîæíîñòåé ýòî ãåïàðèí èëè ÍÌà ñ àñïèðèíîì. Åäèíñòâåííî, åñëè îáíàðóæàòñÿ ÀÒ ê êàðäèîëèïèíó îñîáåííî â âûñîêîì òèòðå, òî íå âñåãäà ÍÌÃ+Àñïèðèí ýôôåêòèâíû, äîáàâëÿþò ê ëå÷åíèþ èììóíîãëîáóëèí.
Åùå â êîíöå 80-õ áûëè íàáëþäåíèÿ ÷òî ïåðåä âûêèäûøåì/îñòàíîâêîé áåðåìåííîñòè âîçíèêàåò ïðåîáëàäàíèå ñâåðòûâàþùåé ñèñòåìû íàä ïðîòèâîñâåðòûâàþùåé äî âñÿêèõ êëèí. ïðîÿâëåíèé, è íàçíà÷åíèå ãåïàðèíà íèâåëèðóåò ýòè íàðóøåíèÿ ãåìîñòàçà, ïîçâîëÿÿ äîíîñèòü áåðåìåííîñòü:
Thromb Res. 1989 Jul 1;55(1):99-107.
Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Woodhams BJ, Candotti G, Shaw R, Kernoff PB.
Haemophilia Centre, Royal Free Hospital, London, England.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 19.06.2003, 19:06
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
Îãðîìíîå ñïàñèáî óâàæàåìûé Dr. Vad çà îòâåò,õîòÿ âñå î÷åíü ñëîæíî äëÿ ìåíÿ.
Ðåçóëüòàòû îáñëåäîâàíèÿ âî âðåìÿ áåðåìåííîñòè (ñðîê 12 íåäåëü) :

Ôèáðèíîãåí 200 (200-400 ìã%)
Òîëåðàíòíîñòü ê ãåïàðèíó 221 (360-660 ñåê)
Òðîìáîòåñò 7 (4-6 ñòåïåíü)
Ðåêàëüöèôèêàöèÿ 127 (80-120 ñåê)
Ñâîáîäíûé ãåïàðèí 3 (5-7 åä)
À×Ò 57 (20-40 ñåê)
ÔÀÊ 180 (120-250 ìèí)

Ìíå ,êàê íå ñïåöèàëèñòó, âèäíî, ÷òî â ýòèõ àíàëèçàõ èìåþòñÿ îòêëîíåíèÿ, õîòÿ âðà÷è ãèíåêîëîãèè óâåðÿþò ìåíÿ, ÷òî çäåñü âñå â ïðåäåëàõ íîðìû, â ÷åì ÿ ñîìíåâàþñü äî ñèõ ïîð (ìîæåò áûòü ÿ è íå ïðàâà ?)

Òðîìáîçû â àíàìíåçå, ó ðîäèòåëåé, ïîñëå îïåðàöèé, òðàâì íå áûëî.
Àíàëèçû,êîòîðûå ïðåäñòàâëåíû â 1-îì ñîîáùåíèè ÿ ñäàâàëà â èíñòèòóòå Ýïèäåìèîëîãèè,àíàëèçû, ïðåäñòàâëåííûå â ýòîì ñîîáùåíèè ÿ ñäàâàëà â âåäîìñòâåííîé ïîëèêëèíèêå ìóæà,ïîýòîìó çàòðóäíÿþñü â òîíêîñòÿõ ïðîâåäåíèÿ èññëåäîâàíèÿ (íå çíàþ íàñêîëüêî ñâåæèé è àêòèâíûé áûë ÀÄÔ,êàêîé çìåèíûé ÿä èñïîëüçîâàëñÿ, è.ò.ä.)
Ñïàñèáî çà îòâåò,óâàæàåìûé Dr. Vad .
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 20.06.2003, 11:13
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Èðèíà!
ßâëÿÿñü íå ñëèøêîì áîëüøèì èíòåðïðåòàòîðîì îòå÷åñòâåííûõ êîàãóëÿöèîííûõ àíàëèçîâ, õî÷åòñÿ âñå æå çàìåòèòü ñëåäóþùåå: âðåìÿ ðåêàëüöèôèêàöèè (îáðàçîâàíèå ñãóñòêà ïîñëå äîáàâëåíèÿ êàëüöèÿ â öèòðàòíóþ ïëàçìó) è À×Ò óâåëè÷åíû, õîòÿ âî âðåìÿ áåðåìåííîñòè ïðîèñõîäèò ïîñòåïåííîå íàðàñòàíèå àêòèâàöèè ñâåðòûâàíèÿ è òåñòû äîëæíû íàîáîðîò áûòü óêîðî÷åíû (íîðìàëüíî-óêîðî÷åííûìè). Ýòî ìîæåò êîñâåííî óêàçûâàòü, åñëè âåðèòü ðåçóëüòàòàì ïðåäûäóùèõ àíàëèçîâ (íîðìàëüíîå À×Ò áåç áåðåìåííîñòè), ÷òî âîë÷àíî÷íûå êîàãóëÿíòû / àíòèôîñôîëèïèäíûå àíòèòåëà ïîÿâëÿþòñÿ/íàðàñòàþò ó Âàñ âî âðåìÿ áåðåìåííîñòè. Òàêæå íåâûñîêèé ñâîá. ãåïàðèí è ïîíèæåííàÿ òîëåðàíòíîñòü ê ãåïàðèíó (óæ íå ïðåäñòàâëÿþ, íà ñêîëüêî ìîæíî äîâåðÿòü ýòèì ïîêàçàòåëÿì) óêàçûâàþò íà íåäîñòàòî÷íîñòü ýíäîãåííîãî ãåïàðèíà è ïîâûøåííóþ ñãóñòêîîáðàçîâàíèå, íåñìîòðÿ íà äîáàâëåíèå ãåïàðèíà in vitro. Ñ ôèáðèíîëèçîì (ÔÀÊ) ó Âàñ âñå â ïîðÿäêå.
Ïîäâîäÿ èòîã, êàê ìèíèìóì, ìîæíî ïðåäïîëîæèòü, ÷òî ó âàñ ïî êðàéíåé ìåðå âî âðåìÿ áåðåìåííîñòè åñòü íàðóøåíèÿ ãåìîñòàçà, êîòîðûå ìîãëè áû ñïðîâîöèðîâàòü ìèêðîòðîìáèðîâàíèå ïëàöåíòû è îñòàíîâêå æèçíåäåÿòåëüíîñòè ïëîäà. Èìåþòñÿ êîñâåííûå ïðèçíàêè, ÷òî ïðèìåíåíèå ãåïàðèíà (íèçêîìîëåêóëÿðíîãî ïðåäïî÷òèòåëüíåå) íà âåñü ïåðèîä áåðåìåííîñòè (ñ ïåðâîé-âòîðîé íåäåëè è ïî 30-32) ìîãëè áû Âàì ïîìî÷ü äîíîñèòü åå. Âñå ÷òî íåïîíÿòíî, ìàëî ïîíÿòíî - ñïðàøèâàéòå, îáüÿñíþ íà äîñòóïíîì óðîâíå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 20.06.2003, 11:17
YBLOKO
Ãîñòü
 
Ñîîáùåíèé: n/a
Åùå ðàç îãðîìíîå ñïàñèáî,Dr. Vad , äëÿ ìåíÿ ýòî î÷åíü âàæíî.
Ñ óâàæåíèåì, Èðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 20.06.2003, 12:56
AlexT AlexT âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 12.06.2003
Ãîðîä: Êðèâîé Ðîã
Ñîîáùåíèé: 861
Ïîáëàãîäàðèëè 64 ðàç(à) çà 61 ñîîáùåíèé
AlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAlexT ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
1 Èçâèíèòå, íå ñìîã óäàëèòü ïîñïåøíîå ñîîáùåíèå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 23.06.2003, 13:55
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,816
Ïîáëàãîäàðèëè 33,433 ðàç(à) çà 31,778 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äëÿ Èðèíû:
ïðèâåäó Âàì íåäàâíî îïóáëèêîâàííóþ çà ðóáåæîì ðåçþìå ñòàòüè ìîñêîâñêèõ àâòîðîâ, ìîæåò ìîæíî èì íàïèñàòü è îáðàòèòüñÿ çà êîíóëüòàöèåé?

Curr Med Res Opin. 2003;19(1):4-12.
Use of the low-molecular-weight heparin nadroparin during pregnancy. A review.
Makatsaria AD, Bitsadze VO, Dolgushina NV.
Moscow Medical Academy, Russia. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Antithrombotic therapy is often used during pregnancy for the treatment and prevention of venous thromboembolism, the prevention of systemic embolism in patients with heart valve prostheses and the prevention of foetal loss in patients with antiphospholipid syndrome. Low-molecular-weight heparins (LMWHs), including nadroparin, have largely replaced unfractionated heparin as the anticoagulant of choice. The use of the LMWH nadroparin in pregnant women at an increased risk of thromboembolism or foetal loss is discussed in this review. Deep vein thrombosis can be effectively treated or prevented with nadroparin without any serious adverse events. Nadroparin 0.1 ml/10 kg s.c. once daily prevents thromboembolic complications in pregnant women with heart valve prostheses. Nadroparin is also effective in preventing foetal loss, through contributing to normal placental development and in decreasing the risk of premature delivery in pregnant women with antiphospholipid syndrome or women with herpes and antiphospholipid syndrome. These results demonstrate nadroparin is effective, easy to administer and associated with a low incidence of foetal and maternal complications. The use of nadroparin at a prophylactic dose of 0.3 ml (2850 IU AXa, 95 IU/kg) (for high-risk patients, 0.3-0.6 ml) s.c. once daily, and a therapeutic dose of 0.1 ml/10 kg (95 IU/kg) s.c. twice daily, is in line with the latest international guidelines of the American College of Chest Physicans.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 03:24.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.